27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Our sample had a mean age of 66.8 (SD = 5.3) years, a mean HAM-D score of 19.4 (SD = 7.5), and a mean PHQ-9 score of 18.0 (SD = 6.3). 5 key findings →
Design: randomized controlled trial Participants: 28 Evidence: high
Full summary, score breakdown and related studies → Original source
Excluding participants with prevalent dementia, n = 1,161 individuals were included. 5 key findings →
Design: longitudinal study Participants: 1,161 Evidence: moderate
Full summary, score breakdown and related studies → Original source
DNS-br total score and majority of the 11 DNS-br neurocognitive subdomain scores were significantly associated with FDG-PET resilience signature, PIB ratio, cerebral gray matter and white matter volume after adjusting for multiple testing. 5 key findings →
Design: cohort study Participants: 283 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Increased BPSD was reported in 59.6% of patients as worsening of preexisting symptoms (51.9%) or as new onset (26%), and requested drug modifications in 27.6% of these cases. 4 key findings →
Participants: 4,913 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Access to affordable, objective and scalable biomarkers of brain function is needed to transform the healthcare burden of neuropsychiatric and neurodegenerative disease. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among the five personality domains, only extraversion was significantly associated with reduced odds of cognitive decline within the intervention group over 24 weeks (fully adjusted model: OR = 0.35; 95% CI: 0.15-0.82). 2 key findings →
Design: randomized controlled trial Participants: 136 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The sample included 55.6% patients with MCI and 56 people with SCD. 5 key findings →
Participants: 55 Evidence: low
Full summary, score breakdown and related studies → Original source
The ICA demonstrated convergent validity with MoCA (Pearson r=0.58, p<0.0001) and ACE (r=0.62, p<0.0001). 5 key findings →
Participants: 230 Evidence: low
Full summary, score breakdown and related studies → Original source
A total of 103 participants completed all investigations and were included in the analysis. 5 key findings →
Participants: 103 Evidence: low
Full summary, score breakdown and related studies → Original source
Thirty-three studies were included. Over half were conducted in Western countries (n =20). 5 key findings →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
One factor accounted for 79.0% of the variance in the UCLALS3; it was perfectly invariant across genders but variant at the metric level across countries. 5 key findings →
Participants: 571 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The results show evidence for increased performance in the assessment of general cognitive functioning in both EGs (p ≤ 0.05). 5 key findings →
Participants: 84 Evidence: low
Full summary, score breakdown and related studies → Original source
All groups showed a worsening of cognitive (39.6%), pre-existing (37.5%), and new (26%) behavioral symptoms, and motor symptoms (35.4%) during the COVID-19 lockdown, resulting in an increased caregiver burden in 26% of cases. 5 key findings →
Participants: 34 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cerebrospinal fluid (CSF) biomarkers are currently the only clinically validated biofluid diagnostic test for Alzheimer's Disease (AD) available in Australia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Environmental pollution exposures, including air, soil, water, light, and noise pollution, are critical issues that may implicate adverse mental health outcomes. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In this paper, we conduct a literature survey on various virtual reality (VR) treatments in psychiatry. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Fifteen articles were included: 8 focussed on the psychiatric symptoms caused by the COVID-19 infection and 7 investigated the impact of social isolation on older adults' neuropsychiatric symptoms. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia syndrome is common and expected to increase significantly among older people and characterized by the loss of cognitive, psychological and physical functions. 2 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Accumulating evidence suggests that brain-derived neurotrophic factor (BDNF) is associated with the pathophysiology of major depressive disorder (MDD). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Affective computing (also referred to as artificial emotion intelligence or emotion AI) is the study and development of systems and devices that can recognize, interpret, process, and simulate emotion or other affective phenomena. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Nutrition is known to play an important role in the pathogenesis of Alzheimer's disease. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is characterized by the extracellular deposition of β-amyloid in senile plaques, the intraneuronal accumulation of hyperphosphorylated tau aggregates as neurofibrillary tangles, and progressive neuronal loss leading to the onset of dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recent studies have shown that immunotherapy clears amyloid beta (Aβ) plaques and reduces Aβ levels in mouse models of Alzheimer's disease (AD), as well as in AD patients. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Early detection of dementia is a key requirement for effective patient management. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
To explore changes in performance, weaknesses, and utilization of the long-term care (LTC) system for older people with disabilities and dementia (OPWDD) in Zhejiang Province, China, thereby providing a reference for decision-making amid a progressively aging population. 2 key findings →
Participants: 1,000 Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →